May 1, 2008 — Allon Therapeutics Inc. (TSX:NPC) presented preclinical data that demonstrate the potential of the Company’s proprietary product candidate AL-309 as a treatment for peripheral neuropathy. AL-309 is the lead candidate in Allon’s second neuroprotection technology platform, derived from Activity Dependent Neurotrophic Factor (ADNF)......AL-309 was tested in two independent studies where diabetes was chemically-induced in rats. As in humans, diabetes in rats leads to progressive development of neuropathy characterized by hypersensitivity to pain, touch, warm and cold stimuli. AL-309 produced a dose-dependent and statistically significant prevention of all of these behavioural end-points showing that it has broad potential for treating the symptoms of nerve damage. In addition, pathology data showed a statistically significant effect on intra-epidermal nerve fiber density demonstrating the capacity to dramatically reduce the loss of nerve fibre... Allon Therapeutics' Press Release -
